Lucas Heller, MD
Endocrinology, Diabetes & Metabolism · Irwin, PANPI 1982970976
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $174,025 of the $198,889 with a category attached, or 87.5%. Novo Nordisk accounts for 90.2% of it on its own, with 32 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 712 payments — averaging $279.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$179K
- Boehringer Ingelheim$9K
- Lilly USA, LLC$7K
- AstraZeneca$694
- Amgen$365
- Sanofi-aventis U.S. LLC$193
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$174,02587%
- Travel & lodging$12,4806%
- Food & beverage$11,8226%
- Education$5630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 395 | $179,409 |
| Boehringer Ingelheim | 44 | $9,353 |
| Lilly USA, LLC | 90 | $6,852 |
| AstraZeneca(2 entities) | 35 | $694 |
| Amgen(2 entities) | 23 | $365 |
| Sanofi-aventis U.S. LLC | 11 | $193 |
| Merck | 14 | $192 |
| Amneal Pharmaceuticals LLC | 11 | $187 |
| Medtronic(2 entities) | 9 | $151 |
| Dexcom, Inc. | 6 | $136 |
| AbbVie | 8 | $132 |
| Insulet Corporation | 6 | $123 |
| Cequr Corporation | 1 | $118 |
| Johnson & Johnson | 10 | $113 |
| Astellas Pharma US Inc | 2 | $99 |
| Abbott | 6 | $91 |
| Tandem Diabetes Care, Inc. | 5 | $87 |
| IBSA Pharma Inc. | 5 | $70 |
| BETA Bionics, Inc. | 4 | $70 |
| Shire North American Group Inc | 4 | $68 |
| Amarin Pharma, Inc. | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Cumberland Pharmaceuticals, Inc. | 2 | $47 |
| Bayer | 3 | $42 |
| Clarus Therapeutics Inc. | 2 | $35 |
| Verity Pharmaceuticals Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $32 |
| Averitas Pharma Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| BD | 1 | $12 |
| Lifescan, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$81,582
- Ozempic$76,305
- JARDIANCE$14,681
- CeQur Simplicity$118
- FARXIGA$110
How this compares
$198,889 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 369 | $557,564 |
| JardianceEmpagliflozin | 246 | $296,767 |
| TrulicityDulaglutide | 192 | $254,368 |
| MounjaroTirzepatide | 130 | $187,413 |
| ProliaDenosumab | 72 | $124,825 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 139 | $101,892 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $64,967 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $48,388 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $41,701 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 15 | $39,899 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $39,637 |
| FarxigaDapagliflozin Propanediol | 46 | $39,129 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $31,719 |
| Humalog Kwikpen U-100Insulin Lispro | 89 | $24,801 |
| Humulin R U-500Insulin Regular, Human | 12 | $24,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $179,409 | $615,484417 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $6,852 | $451,930372 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $9,353 | $326,295275 claims |
| AmgenProlia | $365 | $124,82572 claims |
| AstraZenecaFarxiga | $694 | $39,12946 claims |
| AbbVieSynthroid | $132 | $10,273155 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $187 | $8,567575 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Irwin
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.